The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

PGV-001

personalized genomic peptide vaccine

BIOLOGICAL

Poly-ICLC

immune modulator

BIOLOGICAL

CDX-301

soluble recombinant human protein to work on stem cell

Trial Locations (1)

Icahn School of Medicine at Mount Sinai (ISMMS), New York

All Listed Sponsors

lead

Ashutosh Kumar Tewari

OTHER